We investigated safety, efficacy, and recurrence after postoperative hemithoracic intensity-modulated radiation therapy (IMRT) in patients with malignant pleural mesothelioma treated with extrapleural pneumonectomy (EPP), during the past decade at a single institution. Methods: In 2001 consecutive patients with malignant pleural mesothelioma underwent EPP with planned adjuvant IMRT. Eighty-six patients (64%) underwent hemithoracic IMRT; the rest were not eligible because of postoperative complications, disease progression, or poor performance status. We assessed toxicity, survival, and patterns of failure in these 86 patients. Toxicity was scored with the Common Terminology Criteria for Adverse Events version 4.0; survival outcomes were estimated with the Kaplan-Meier method; and locoregional patterns of failure were classified as infield, marginal, or out-of-field. Risk factors related to survival were identified by univariate and multivariate Cox regression analysis. Results: Median overall survival time for all 86 patients receiving IMRT was 14.7 months. Toxicity rates of grade of 3 or more were: skin 17%, lung 12%, heart 2.3%, and gastrointestinal toxicity 16%. Five patients experienced grade 5 pulmonary toxicity. Rates of locoregional recurrence-free survival, distant metastasis-free survival, and overall survival (OS) were 88%, 55%, and 55% at 1 year and 71%, 40%, and 32% at 2 years. On multivariate analysis, pretreatment forced expiratory volume in 1 second, nonepithelioid histology, and nodal status were associated with distant metastasis-free survival and OS. Conclusion: IMRT after EPP is associated with low rates of locoregional recurrence, though some patients experience life-threatening lung toxicity. Tumor histology and nodal status can be helpful in identifying patients for this aggressive treatment.
M alignant pleural mesothelioma (MPM) is a rare and deadly cancer that primarily occurs decades after exposure to asbestos. Outcomes have remained dismal despite aggressive treatment strategies. Extrapleural pneumonectomy (EPP) is an aggressive and increasingly controversial approach 1 that can be used to surgically treat this malignancy, although patients remain at high risk for locoregional failure and nearly all die of the disease even after EPP. 2 Hemithoracic radiation therapy has been used to control microscopic residual disease and minimize the risk of locoregional recurrence (LR). Although the initial reports of this approach involved conventional three-dimensional conformal radiation therapy, 3, 4 subsequent studies suggest that postoperative radiation is feasible when delivered as intensity-modulated radiation therapy (IMRT), with promising rates of locoregional control. 5 However, results of this technique from large databases 6, 7 other than the Surveillance, Epidemiology, and End Results database are limited. 8 The purpose of this study was to summarize our experience with this strategy at a high-volume tertiary cancer care center over the past decade, focusing on toxicity and survival outcomes. We also analyzed patterns of failure of this combined-modality technique to estimate the percentage of patients who experience recurrences at the radiation margin and to determine whether the radiation fields currently being used for this purpose are appropriate. these patients (64%) ultimately underwent hemithoracic IMRT and their characteristics are listed in Table 1 . We routinely recommend hemithoracic IMRT after EPP when patients recover from surgery, typically within 2 to 3 months, if the patient can tolerate it. Of the 50 patients who did not undergo IMRT after EPP in this study, 22 were not treated because of poor performance status after surgery; 11 died before they could be considered for radiation (6 from pneumonia or acute respiratory distress syndrome, 1 from pulmonary embolism, 1 from bronchopleural fistula, 1 from intraoperative bleeding followed by cardiac arrest, and 2 from cardiac arrest of unknown causes); 12 patients were not considered candidates for radiation because of distant metastasis (DM) or significant local recurrence (LR) found at or before computed tomography (CT) treatment simulation; and five refused radiation or were lost to follow-up. Chemotherapy regimens included cisplatin/ pemetrexed (n = 25), cisplatin alone (n = 4), cisplatin/ gemcitabine (n = 3), carboplatin/pemetrexed (n = 2), and dasatinib+/−systemic therapy (n = 8).
It is evident from examining Table 1 that there are no significant differences in the majority of variables between those patients who received IMRT versus those who did not, including performance status at the time of diagnosis, stage, and histology, further highlighting the intention to treat approach that is taken in all patients who receive an EPP. Indeed, not one patient who underwent EPP alone received adjuvant chemotherapy, which supports the premise that this subgroup of patients was not eligible for any adjuvant therapy.
Surgery
All patients underwent staging studies, including positron emission tomography or CT, bronchoscopy, laparoscopy, and mediastinoscopy before surgery to identify transdiaphragmatic extension and contralateral hemithoracic disease; none had evidence of DM before EPP. Pulmonary and renal function was evaluated with spirometry, quantitative ventilation/perfusion scanning, and radioisotope renography. The surgical procedure involved an en bloc resection of the lung, parietal pleura, visceral pleura, ipsilateral pericardium, and diaphragm, with reconstruction of the pericardium and diaphragm with polytetrafluoroethylene, as described previously. 9 Complications of surgical resection are depicted in Table 2 .
Radiation Therapy
All patients underwent four-dimensional CT-based treatment simulation before radiation therapy. Simulation took place while the patients were supine and immobilized in an upper body cradle, with both arms overhead, grasping a T-bar. A bolus, 3.0-3.5 cm circumference, was placed over the incision and drainage sites. The ipsilateral hemithorax was contoured as the clinical target volume, which included the pleural space, scars, drain sites, and involved nodal stations. These contours were drawn in consultation with the operating surgeon to identify specific regions that required a boost. This volume was then expanded to include a margin for internal motion, and an additional 0.5-to 1.0-cm margin was added to account for patient movement (the planning target volume). Details of our radiation treatment planning approach have been published elsewhere. 10 The dose prescribed to the planning target volume was 45 to 50 Gy in 25 daily fractions. Thirteen patients received a radiation boost of 55 to 60 Gy in areas identified by the surgeon as being at high risk for residual disease or as positive margins. Standard dose constraints in the remaining lung included a mean lung dose less than 8.0 Gy; the esophagus (V 50 ) received less than 50%, and the mean dose to the esophagus was less than 34 Gy. Mean dose to the heart was kept at less than 26 Gy and the heart V 30 was less than or equal to 45%. The maximum dose to the spinal cord was kept at less than 45 Gy. Liver constraints were: mean dose to the liver was less than 30 Gy and the liver V 30 was less than or equal to 40%. Finally, the dose to at least two thirds of the contralateral kidney was kept below 30 Gy. Interval histories and physical examinations were done weekly during treatment, after treatment events, and at each follow-up visit. CT imaging was obtained every 3 months for 2 years after treatment and yearly, thereafter.
IMRT Toxicity Assessment
Treatment-related toxicity was assessed weekly during radiation therapy, at 4 to 6 weeks after treatment, and then every 3 months thereafter. Toxicity was scored according to the Common Terminology Toxicity Criteria for Adverse Events version 4.0 and focused on esophageal, pulmonary, and cardiac toxicity.
Patterns of Failure
Patterns of failure were characterized in all patients who experienced disease recurrence. Treatment failure within the ipsilateral hemithorax was considered LR, and all other sites of failure were considered DM. For patients who experienced LR, archived radiation treatment plans were obtained and fused with the image that revealed the recurrence to establish whether the failure was in-field, marginal, or out-of-field. Marginal failures were those in which the recurrence lay partially within and partially outside the isodose line representing the prescribed dose.
Statistical Considerations
Data were analyzed with Stata/SE 11.1 (StataCorp LP, College Station, TX). Actuarial rates of LR-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were estimated by using the Kaplan-Meier method and compared with log-rank tests. Cox proportional hazards models were developed to identify associations between patient-and disease-related characteristics and the survival endpoints. Significance was determined using α = 0.05, and variables found to be significant in univariate analysis were then tested in multivariate analysis. Survival was calculated from the date of surgery.
RESULTS
The median follow-up time for all 86 patients receiving EPP+IMRT was 10.2 months (range, <1-99.3 months), and the median follow-up time for all patients alive at the time of analysis was 13.9 months (range, 2.7-99.3 months). The median interval between surgery and IMRT was 2.4 months (range, 1.3-7.0 months).
Toxicity
Toxic effects secondary to IMRT are shown in Table 3 . Almost all patients experienced gastrointestinal symptoms of grade 2 or more, primarily nausea, esophagitis, or both. Toxicity rates of grade 3 or higher were as follows: skin, 17.4% (n = 15); gastrointestinal (e.g., esophagitis/nausea), 16 .3% (n = 14); heart, 2.3% (n = 2); and lung, 11.6% (n = 10). Five patients experienced grade 5 toxicity, which were all pulmonary (3 radiation pneumonitis and 2 bronchopleural fistulae). Of the two patients who experienced cardiac toxicity of grade 3 or more, one had a pericardial effusion (grade 3), and the other developed severe cardiomyopathy with markedly reduced ejection fraction (grade 4). Other grade 3 toxicities included grade 3 dyspnea 2 to 6 months after completing IMRT (n = 2) and a seroma, possibly caused by radiationrelated chest wall disruption, requiring surgery. Patients who received induction chemotherapy did not experience higher rates of severe toxicity (p > 0.05), though the small number of such patients (n = 20) precluded full statistical analysis.
Survival and Patterns of Failure
At 1 year, OS rates were 54%, LRFS 88%, and DMFS 71%; corresponding rates at 2 years were OS 32%, LRFS 55%, and DMFS 40%, and at 3 years were OS 22%, LRFS 54%, and DMFS 21% (Fig. 1) . Fourteen patients (16%) experienced LR and 51 patients (59%) had DM. Only two patients experienced LR alone; the other 12 patients had both LR and DM. Sites of DM were as follows: contralateral hemithorax, 41% (n = 35); abdomen and pelvis, including liver, 28% (n = 24); and bones, 7% (n = 6). Some patients experienced recurrence at more than one distant site. Of the 14 patients who experienced LR, eight had multiple recurrences within the high-dose region, five patients had recurrences on the margin of a hemithoracic field (in a subcarinal lymph node, an ipsilateral subpectoral lymph node, a retrosternal mass, within a solitary pleural mass in the ipsilateral hemithorax, and in multiple mediastinal lymph nodes near the margin of the radiation field), and one patient had a recurrence in the ipsilateral supraclavicular region.
Recurrence patterns for two patients, who experienced LR, one in a cold spot within the radiation field and the other in both a high-dose region and near the margin of the field, are shown in Figure 2 .
In Figure 3 , we have depicted a comparison of those patients who completed IMRT after EPP (median OS 14.7 months) versus those patients who received EPP alone (median OS 4.5 months), both with respect to OS and disease-free survival. It is evident that survival outcomes are substantially improved with combined-modality therapy, primarily because inherent selection criteria for IMRT after EPP are factors that would affect these survival endpoints, such as poor performance status, early treatment failure, and death (with only 5 patients foregoing IMRT strictly because of patient refusal).
Factors Predicting Survival
Multivariate analysis indicated that the following factors were predictive of worse DMFS and OS in those patients receiving EPP+IMRT: nonepithelioid histology, higher nodal status, and lower pretreatment forced expiratory volume in 1 second tested as a continuous variable (Table 4 ). Higher hazard ratios in this table indicate an increased risk of an event (e.g., DM or death, respectively). No variables were found to be associated with LRFS. Grouping patients according to nodal status and histology also produced subgroups with distinct prognoses in terms of DM (Fig. 3A) and OS (Fig. 3B) . Chemotherapy was not associated with any survival outcomes (p > 0.05).
DISCUSSION
Apart from Surveillance, Epidemiology, and End Results analyses, the current study represents the largest known series with complete clinical information for evaluating survival outcomes after EPP followed by IMRT for MPM. Our pertinent findings can be summarized as follows. First, a significant number of patients (50, or 37%) who underwent EPP with planned adjuvant radiation did not receive IMRT because of poor performance status, postoperative complications, or the early development of DM. In addition, some patients did not receive postoperative radiation therapy for several months after treatment, because of either the administration of chemotherapy or recovery from surgery, thereby questioning the adjuvant nature of this approach. Second, the predominant pattern of failure after this combined-modality approach was DM, and among those patients who experienced LR, most had treatment failures at multiple sites within the high-dose radiation region, suggesting that radiation doses currently being used for this purpose do not control disease in at least some of these patients. Third, although this aggressive approach could produce significant toxicity (primarily gastrointestinal and dermatologic effects that required rigorous monitoring and care), the incidence of cardiopulmonary toxicity of grade 3 or lesser was much lower (14%). Nevertheless, patients considering this treatment should be informed that even when FIGURE 1. Kaplan-Meier survival curves for patients treated with extrapleural pneumonectomy followed by intensity-modulated radiation therapy for malignant pleural mesothelioma. A, Locoregional-progression-free survival; (B), distant metastasis-free survival; (C), overall survival. stringent dosimetric constraints are used, this approach carries a low, although nonnegligible, risk (approximately 6%) of potentially fatal complications. Finally, histologic type and nodal status were the two primary disease factors that influenced survival outcomes-further evidence that this aggressive approach should be reserved mainly for patients with epithelioid tumors and negative mediastinal lymph nodes.
We previously reported outcomes and patterns of failure among 100 patients treated with EPP with or without adjuvant IMRT. 5 In that study, for the 61 patients who underwent IMRT from 1999 to 2005, median OS was 14.2 months, 3-year OS was 20%, and eight patients (13%) had LR. The current analysis, with a greatly expanded number of patients and with the increased use of positron emission tomography scan to evaluate recurrence and patterns of failure in the recent cohort, corroborated our previous finding of high rates of local control while closely evaluating the benefit of IMRT. Indeed, results from the current study compare favorably with those in other published studies of radiation after EPP. In one such study, among 13 patients treated with IMRT at Duke University, six (46%) had local failure. 11 In another study at Memorial Sloan Kettering Cancer Center, a matched photon and electron (MPE) technique was used to deliver 54 Gy of hemithoracic radiation after EPP to a series of 61 patients. 4 Although the median OS time in that study was 17 months, the median OS for the subset of patients most analogous to those in the current study with stage III or IV disease, was just 10 months. 3 Use of IMRT to deliver hemithoracic RT after EPP has been linked with high rates of fatal pneumonitis. 12 Another risk factor for the development of severe pulmonary events has been the use of intraoperative cisplatin. 13 However, since these studies were published, several others have demonstrated that IMRT can provide both dosimetric superiority and good clinical outcomes when appropriate dose constraints are used. 14 For example, in one analysis of 78 patients treated with MPM, 67% of isolated local failures were in areas of dose inhomogeneity that would have had better coverage with IMRT. 15 Other studies from M.D. Anderson Cancer Center 5 and other institutions 6, 7 have shown low rates of high-grade pneumonitis (5% in this study) and median survival times of 16 months or more with the use of IMRT. With the increasing adoption of IMRT and the growing acceptance that the mean dose to the ipsilateral lung should not exceed 8.0 Gy, the rates of adverse clinical consequences of the low-dose bath created by IMRT have been sharply reduced. Use of newer technologies such as volumetric-modulated arc therapy may also reduce patient treatment times while offering target volume coverage similar to IMRT with reduced contralateral lung doses. 16 Our finding that IMRT after EPP led to a low rate of LR (16%), defined as recurrence in the ipsilateral hemithorax, is encouraging. Indeed, we found that OS thus correlated much more directly with time to DM, which led to a median OS time of 14.7 months. These findings are consistent with prior phase II studies examining the efficacy of trimodality therapy, in which OS times in excess of 20 months have been consistently achieved. 17 In one such analysis, patients in a phase II trial of neoadjuvant cisplatin and pemetrexed followed by EPP and IMRT/MPE had a median OS time of 29.1 months. 7 In another series, patients with N0 disease who successfully completed trimodality therapy at Princess Margaret Hospital had median OS times as long as 59 months. 6 Achieving OS for longer than 5 years has proven to be much more difficult, and will likely necessitate the development of improved systemic regimens. Over the past decade, the addition of antifolates to platinum regimens has been shown to improve OS rates in several trials. 18 With the recognition that MPMs often express activated Src kinase, prospective trials of dasatinib are also being undertaken in potentially resectable cases. 19 Further results from studies such as these are eagerly anticipated.
Finally, consistent with prior reports from our institution and others, 5, 20, 21 we found that patients with sarcomatoid or biphasic histology and mediastinal nodal involvement had substantially reduced survival outcomes with this aggressive technique. It is important to emphasize that largely based on findings over the past decade, which have shown, even with modern surgical and radiation techniques poor prognosis in patients who have these disease characteristics, the practice patterns at our institution have changed over time. The standard practice at our institution for high-risk patients is currently as follows. For patients with sarcomatoid disease, no surgery is recommended. Patients with known biphasic histology or N2 stage are offered either lung-sparing surgery or no surgery, but an EPP is not currently recommended. In addition to the weaknesses inherent in any retrospective study, the current analysis had several limitations. First, our patterns-of-failure analysis was limited by the lack of histologic confirmation of recurrence in some cases, which would be available in a controlled prospective analysis. In these instances, the assessment of failure was made on the basis of the clinical and imaging data available in the medical record. Second, small patient numbers precluded full analysis of the effect of chemotherapy (e.g., the specific regimen, number of cycles, or timing) with regard to patterns of failure and survival outcomes. Third, as alluded to above, it is important to stress that recent trials of multimodality therapy involving lung-sparing procedures have been published that demonstrate similar improved outcomes with these techniques when compared with EPP. 1, [22] [23] [24] Therefore, there remains no consensus as to the optimal approach in this setting, and lung-sparing techniques such as pleurectomy or decortication should be strongly considered, particularly in patients who are borderline candidates for EPP. Finally, although we have included a comparison of OS and DFS outcomes in patients who received EPP + IMRT versus EPP alone as mentioned above, this retrospective comparison is subject to substantial bias inherent in the use of a comparison group that received EPP alone because of underlying factors that portend a worse prognosis. Indeed, we found in the current study that the vast majority of patients who did not undergo combined-modality treatment could not do so because of recurrence, toxicity, or poor performance status that rendered postoperative radiation unfeasible. In other words, our approach in all patients who undergo EPP is an intention to treat with IMRT as well, with unanticipated early recurrences, postoperative complications, or declines in performance status precluding treatment with postoperative radiation.
CONCLUSIONS
Although lung-sparing surgery has emerged as a viable approach for patients with MPM, our results demonstrate that definitive EPP followed by IMRT for MPM produces high rates of locoregional control. While the rates of dermatitis and gastrointestinal symptoms were significant, the incidence of high-grade cardiopulmonary toxicity was low (although nonnegligible) when stringent dosimetric constraints were used. Technical advances may eventually permit better local control with less toxicity. However, even patients in whom locoregional control is achieved are at risk of developing DM, such that similar survival outcomes have been shown in trials using chemotherapy alone. 25 Thus, further trials of systemic agents, including targeted therapies, are indicated. Hazard ratios represent the risk of death, locoregional recurrence, and distant metastasis. hr, hazard ratio; CI, confidence interval; FEV1, forced expiratory volume in 1 second.
